# COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

Study · id `cardio:ct-nct05734690` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05734690](<https://clinicaltrials.gov/study/NCT05734690>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05734690

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 503 participants.

## Technical summary

Registry record NCT05734690. Randomized; no masking; primary purpose treatment. Start 2023-05-05 (actual); primary completion 2025-05-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 503 participants (enrolled count; ClinicalTrials.gov record NCT05734690, source copy `cardio:ctgov-nct05734690-2026-02-06`, retrieved 2026-10-31)
- Started: 2023-05-05 (actual) (ClinicalTrials.gov record NCT05734690, source copy `cardio:ctgov-nct05734690-2026-02-06`, retrieved 2026-10-31)
- Primary completion: 2025-05-19 (actual) (ClinicalTrials.gov record NCT05734690, source copy `cardio:ctgov-nct05734690-2026-02-06`, retrieved 2026-10-31)
- Completion: 2025-06-09 (actual) (ClinicalTrials.gov record NCT05734690, source copy `cardio:ctgov-nct05734690-2026-02-06`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT05734690, source copy `cardio:ctgov-nct05734690-2026-02-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05734690-2026-02-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure
- Acronym: COPILOT-HF
- Condition: Heart Failure
- Intervention (Drug): SGLT2i, beta blocker, ARNI, MRA, MTD
- Intervention (Behavioral): Education-First
- Lead sponsor: Brigham and Women's Hospital
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 979c25d6655c3e3c684fd1827f1e2535432a1904dc19df732141b00bb7ab5738
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
